|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
2
|
|
gptkbp:bfsParent
|
gptkb:physicist
|
|
gptkbp:activities
|
broad spectrum
|
|
gptkbp:approves
|
gptkb:1987
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Ciprofloxacin
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:class
|
gptkb:fluoroquinolone
|
|
gptkbp:clinical_trial
|
Phase III trials
Phase IV trials
|
|
gptkbp:contraindication
|
gptkb:Insurance_Company
tendon rupture
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:formulation
|
oral tablet
oral suspension
IV solution
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cipro
|
|
gptkbp:indication
|
skin infections
urinary tract infections
gastrointestinal infections
respiratory tract infections
bone and joint infections
|
|
gptkbp:ingredients
|
gptkb:ciprofloxacin
C17 H18 F N3 O3
|
|
gptkbp:interacts_with
|
gptkb:theophylline
gptkb:warfarin
antacids
|
|
gptkbp:is_atype_of
|
J01 M A02
|
|
gptkbp:is_available_on
|
gptkb:tablet
suspension
injection
|
|
gptkbp:is_used_for
|
bacterial infections
|
|
gptkbp:lifespan
|
4 hours
|
|
gptkbp:manager
|
oral
intravenous
|
|
gptkbp:manufacturer
|
gptkb:Bayer_AG
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:Brazil
gptkb:India
gptkb:Japan
gptkb:Mexico
gptkb:South_Africa
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:side_effect
|
dizziness
headache
nausea
diarrhea
liver toxicity
insomnia
photosensitivity
hypersensitivity reactions
QT prolongation
CNS effects
|
|
gptkbp:type_of
|
85721-33-1
|